Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for NeuroPace (NPCE) over the last 6 years, with Q3 2025 value amounting to $53000.0.

  • NeuroPace's Gains from Investment Securities fell 2205.88% to $53000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $547000.0, marking a year-over-year decrease of 4810.25%. This contributed to the annual value of $881000.0 for FY2024, which is 37968.25% up from last year.
  • Per NeuroPace's latest filing, its Gains from Investment Securities stood at $53000.0 for Q3 2025, which was down 2205.88% from $174000.0 recorded in Q2 2025.
  • In the past 5 years, NeuroPace's Gains from Investment Securities registered a high of $10.7 million during Q3 2022, and its lowest value of -$817000.0 during Q1 2023.
  • In the last 5 years, NeuroPace's Gains from Investment Securities had a median value of $118500.0 in 2022 and averaged $1.1 million.
  • Per our database at Business Quant, NeuroPace's Gains from Investment Securities surged by 2091333.33% in 2021 and then crashed by 10515.61% in 2022.
  • Over the past 5 years, NeuroPace's Gains from Investment Securities (Quarter) stood at $2.1 million in 2021, then plummeted by 94.56% to $115000.0 in 2022, then surged by 130.43% to $265000.0 in 2023, then crashed by 65.28% to $92000.0 in 2024, then plummeted by 42.39% to $53000.0 in 2025.
  • Its Gains from Investment Securities was $53000.0 in Q3 2025, compared to $174000.0 in Q2 2025 and $228000.0 in Q1 2025.